TCR2 Tx Appoints Peter Olagunju as Chief Technical Officer
On Tuesday, July 20, TCR2 Therapeutics announced (press release) the appointment of Peter Olagunju as their first Chief Technical Officer (CTO). Below, Celltelligence provides insights on how Peter Olagunju’s extensive cell therapy development and manufacturing experience could accelerate the development and commercialization of TCR2 Tx’s lead asset, gavo-cel (mesothelin targeted TRuC-T) in solid tumors.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.